McKesson (NYSE:MCK) Issues Q2 2025 Earnings Guidance

McKesson (NYSE:MCK) updated its second quarter 2025 earnings guidance on Friday. The company provided EPS guidance of 6.700-7.000 for the period, compared to the consensus EPS estimate of 7.240. The company issued revenue guidance of -.

Analysts Set New Price Targets

A number of brokerages recently commented on MCK. Mizuho upped their target price on McKesson from $540.00 to $570.00 and gave the company a neutral rating in a report on Thursday, August 8th. StockNews.com downgraded McKesson from a strong-buy rating to a buy rating in a report on Friday, August 9th. Barclays increased their price objective on McKesson from $596.00 to $616.00 and gave the stock an overweight rating in a report on Thursday, August 8th. Wells Fargo & Company increased their price objective on McKesson from $502.00 to $551.00 and gave the stock an equal weight rating in a report on Thursday, May 9th. Finally, Citigroup increased their price objective on McKesson from $620.00 to $670.00 and gave the stock a buy rating in a report on Friday, July 19th. Two investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus target price of $624.93.

McKesson Price Performance

Shares of McKesson stock traded down $9.80 during trading on Friday, hitting $504.95. 393,526 shares of the company’s stock traded hands, compared to its average volume of 752,136. McKesson has a 1 year low of $412.64 and a 1 year high of $637.51. The stock has a market capitalization of $65.61 billion, a P/E ratio of 23.00, a PEG ratio of 1.29 and a beta of 0.44. The business has a 50-day simple moving average of $576.35 and a 200-day simple moving average of $557.33.

McKesson (NYSE:MCK) last released its quarterly earnings data on Wednesday, August 7th. The company reported $7.88 EPS for the quarter, beating the consensus estimate of $7.21 by $0.67. The company had revenue of $79.28 billion for the quarter, compared to analysts’ expectations of $82.53 billion. McKesson had a negative return on equity of 242.57% and a net margin of 0.94%. McKesson’s revenue was up 6.4% compared to the same quarter last year. During the same period last year, the firm posted $7.27 earnings per share. On average, equities analysts predict that McKesson will post 32.14 earnings per share for the current fiscal year.

McKesson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 1st. Shareholders of record on Monday, September 2nd will be given a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 0.56%. This is a boost from McKesson’s previous quarterly dividend of $0.62. The ex-dividend date of this dividend is Friday, August 30th. McKesson’s dividend payout ratio (DPR) is presently 12.69%.

Insiders Place Their Bets

In other McKesson news, CEO Brian S. Tyler sold 3,753 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $580.92, for a total value of $2,180,192.76. Following the transaction, the chief executive officer now directly owns 86,092 shares of the company’s stock, valued at $50,012,564.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Leann B. Smith sold 600 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $585.53, for a total value of $351,318.00. Following the transaction, the executive vice president now owns 2,022 shares of the company’s stock, valued at $1,183,941.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Brian S. Tyler sold 3,753 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $580.92, for a total value of $2,180,192.76. Following the completion of the transaction, the chief executive officer now directly owns 86,092 shares in the company, valued at approximately $50,012,564.64. The disclosure for this sale can be found here. Over the last three months, insiders have sold 8,106 shares of company stock valued at $4,881,001. Insiders own 0.11% of the company’s stock.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.